P rimary hyperparathyroidism is defined as elevated serum calcium levels with inappropriate elevation of parathyroid hormone (PTH) levels. In the majority (75%-85%) of patients, primary hyperparathyroidism is the result of a single parathyroid adenoma; the remaining patients have involvement of more than 1 parathyroid gland (multigland hyperplasia). 1 Parathyroidectomy is currently the only cure for primary hyperparathyroidism. Historically, the gold standard for parathyroidectomy involved bilateral cervical exploration and identification of all parathyroid glands, with removal of only enlarged glands. With the advent of intraoperative PTH (IOPTH) monitoring and improved radiographic techniques for preoperative gland localization imaging, minimally invasive parathyroidectomy (MIP) has become the favored approach. Minimally invasive parathyroidectomy has been demonstrated to have similar success rates as bilateral exploration, with lower rates of endocrine-specific complications, such as recurrent laryngeal nerve injury and permanent hypoparathyroidism. 2 Monitoring IOPTH levels involves sampling of PTH values preoperatively and intraoperatively, after resection of abnormal parathyroid glands. The definition of a successful parathyroidectomy using IOPTH data varies by institution. Two common criteria include (1) a decrease of more than 50% from the highest preexcision value (the Miami criterion) or (2) a decrease of more than 50% from the highest preexcision value and into the normal range of the PTH assay. [3] [4] [5] Despite the various institutional differences, all current criteria rely solely on absolute IOPTH values and few studies have investigated the effect of patient factors on IOPTH elimination that could alter these values. 3, [5] [6] [7] [8] [9] [10] Therefore, the purpose of this study was to identify patient characteristics (age, sex, race, body mass index [BMI] , and/or renal function) that may affect the half-life of PTH and, if so, to determine if new criteria are needed for IOPTH monitoring during parathyroidectomy.
Methods

Patients
Following institutional review board approval, patient data were retrospectively collected from a single institution's prospectively collected parathyroidectomy database populated from August 2005 to April 2011. Inclusion criteria for the study were patients with sporadic primary hyperparathyroidism due to a single adenoma who underwent initial parathyroidectomy with a complete IOPTH profile, consisting of IOPTH levels assayed at 0 to 4 minutes, 5 to 9 minutes, 10 to 14 minutes, and 15 to 40 minutes after adenoma resection. Of the initial 314 patients, 8 patients were excluded because of nonstandard IOPTH profiles. The final study cohort consisted of 306 patients. Queried patient data consisted of age, sex, race, BMI (calculated as weight in kilograms divided by height in meters squared), preoperative serum calcium level, preoperative PTH level, glomerular filtration rate (GFR) (Modification of Diet in Renal Disease formula), and IOPTH concentrations with corresponding time values. All 306 patients underwent preoperative localization using cervical ultrasonography and technetium Tc 99m-labeled sestamibi scans.
11 Since 2009, sestamibi scan was routinely performed with single-photon emission computed tomography; patients with discordant ultrasonography and sestamibi-single-photon emission computed tomography findings underwent a 4-dimensional computed tomography scan.
Intraoperative PTH Monitoring
All patients underwent MIP with IOPTH monitoring. Our institution's IOPTH monitoring protocol consists of obtaining IOPTH levels from a peripheral blood sample following anesthesia induction and prior to neck incision (baseline), at adenoma resection (zero value), and subsequently at 5-minute intervals (5, 10, and 15 minutes) after adenoma resection. Our institution's criteria for intraoperative biochemical cure at 10 minutes after adenoma resection are defined as (1) PTH level decline of at least 50% from either the baseline or the zero value, whichever is higher, and (2) 
Kinetic Analyses
Individual IOPTH data sets were modeled using an ideal single- [IOPTH](t) = A 0 e −kt + C
For the analysis, it was assumed that the contribution of the nonadenomatous parathyroid glands to the IOPTH profile was constant.
12 Least squares nonlinear regression modeling of the IOPTH data sets, based on Equation 1, was performed using an open-source implementation, ALGLIB, of the Levenberg-Marquardt algorithm in Visual Studio C++ (Microsoft). 13 The program yielded the kinetic decay constant, k, constant term, A 0 , and constant function, C, for each patient. Correlation coefficients were calculated to verify model conformity, and IOPTH half-life values, ln(2)/k, were then determined (Excel; Microsoft).
Statistical Analyses
Nonparametric statistical analyses were performed because the IOPTH half-life values were nonnormally distributed in a positively skewed fashion. Nonparametric Wilcoxon rank sum test and Spearman rank correlation tests were used for univariate tests of association between patient demographics or laboratory data and IOPTH half-life. Median regression was used in multivariate analysis of IOPTH half-life. Variables in the model included those with P < .10 on univariate analysis and a priori hypothesized risk factors. Median regression model selection was performed manually with a significance level of <.05. All statistical analysis was performed in SAS version 9.2 (SAS Institute Inc).
Results
Cohort Summary Statistics
The . The median preoperative serum calcium level was 10.7 mg/dL (IQR, 10.3-11.3 mg/dL) (to convert to millimoles per liter, multiply by 0.25) and the median baseline preoperative PTH level was 169.5 pg/mL (IQR, 118.0-169.5 pg/mL) (to convert to nanograms per liter, multiply by 1). No patient was taking cinacalcet at the time of surgery; 39 patients (13%) were taking a bisphosphonate at the time of surgery.
Kinetic Analyses
On kinetic analysis, Equation 1 was shown to fit individual IOPTH data with high conformity, as validated by a nonlinear regression correlation coefficient IQR of 0.9978 to 0.9999. The median calculated IOPTH half-life for the entire cohort was 3 minutes, 9 seconds (IQR, 2 minutes, 37 seconds to 4 minutes; mean, 3 minutes, 28 seconds). Calculated IOPTH half-life values were independent of the immunoassay implemented (P = .11).
Statistical Analyses
There was an association between race and IOPTH half-life (Table) ; black patients demonstrated a longer IOPTH half-life than white patients (3 minutes, 50 seconds vs 3 minutes, 7 seconds; P < .01). Hispanic patients had a shorter IOPTH half-life (2 minutes, 50 seconds) but the small Hispanic sample size (n = 4) limited our ability to make any inferences for this subset of the population. There was a trend toward an association between BMI and IOPTH half-life (P = .06); patients with a higher BMI had a longer IOPTH half-life. Similarly, there was a trend toward an association between sex and IOPTH halflife; men had a median IOPTH half-life that was 6 seconds longer than women (3 minutes, 14 seconds vs 3 minutes, 8 seconds; P = .06). There was no association between IOPTH halflife and patient age, renal function, preoperative serum calcium or PTH levels, or preoperative use of bisphosphonates.
Race, sex, and BMI along with a priori variables GFR and age plus an age × BMI interaction factor were then considered in multivariate analysis. Controlling for these factors, race, sex, and GFR were not significant. Significant predictors of IOPTH halflife were BMI (P = .04) and the age × BMI interaction factor (P < 
Median IOPTH half-life increases with increasing BMI, but the predictive value of BMI declines with increasing age (Equation 2 and Figure) . Therefore, the effect of BMI is negligible once a patient is older than 55 years, because the effect of BMI was not statistically significant until the age × BMI interaction was considered.
Postoperative Follow-Up
At the time of last follow-up, the median calcium level for the study cohort was 9.4 mg/dL (range, 7.4-11.3 mg/dL) and median PTH level was 22.6 pg/mL (range, 2.5-200.1 pg/mL). No patient had persistent disease and only 1 patient (0.3%) had a known recurrence, defined as both a serum calcium level and PTH level more than the upper limit of normal, at last follow-up, with a serum calcium level of 11.3 mg/dL and PTH level of 75 pg/mL (IOPTH half-life, 2 minutes, 40 seconds). Median follow-up was 835 days (2.3 years; median, 6-2193 days [0.02-6.0 years]). Selection of a kinetic model that most closely approximated the IOPTH elimination data of the cohort was paramount to quantifying IOPTH elimination in this study. Previous IOPTH kinetic studies have implemented either a multiexponential decay model (multiphase) or a singleexponential decay model. 12,14,17 Maier et al 14 used a 2-phase exponential decay model; however, this required multiple IOPTH data points that were not obtained in our cohort. Two single-phase models dependent on first-order kinetics have previously been described. Libutti et al 17 used the preexcision PTH level as the initial data point, required 3 intraoperative data points, and assumed that the nonadenomatous glands' contribution to serum PTH level immediately increased as a function of the intraoperative decay constant, k, and time after adenoma resection. In contrast, in the model used by Bieglmayer et al, 16 the initial data point was the PTH level at the time of adenoma resection, 4 intraoperative data points were required, and it was assumed that the nonadenomatous glands' contribution to serum PTH level was constant after adenoma resection. Both of these models yielded identical IOPTH half-lives in an ideal setting. 16 ) were independent preoperative predictors of a slower decrease in IOPTH concentration between the PTH values at baseline and 10 minutes after adenoma resection. In this study, however, GFR was not found to be an independent predictor of IOPTH half-life on univariate or multivariate analysis. The results of this study do show BMI and an age × BMI interaction factor to be predictors of IOPTH half-life on multivariate analysis. The relationship between BMI and PTH metabolism is unclear. Animal models have shown that the hepatic Kupffer cell is a major determinant of the first phase of PTH elimination, which corresponds to the elimination phase of our model. 18, 19 Therefore, it is possible that patients with higher BMI, perhaps because of a higher likelihood of steatohepatitis, may have reduced hepatic metabolism of PTH.
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There are several limitations to this study, including those inherent to a retrospective medical record review. Furthermore, recorded times for IOPTH blood draws were approximate and may not reflect exact intervals; therefore, the calculated IOPTH half-life may be inaccurate. However, since the predicted half-life differences were short (seconds), this limitation was not likely to affect the outcomes of this study.
In conclusion, patient race, sex, and renal function were not independent predictors of IOPTH half-life in patients with primary hyperparathyroidism undergoing parathyroidectomy. Interestingly, BMI and an age × BMI interaction factor may predict IOPTH half-life. However, predicted IOPTH halflife differences based on BMI are small, on the order of seconds, thus limiting the translation of the findings into clinical practice. Furthermore, the overall success rate in this cohort of patients was more than 99%, providing further evidence that these relatively small differences in IOPTH half-life are not clinically significant. Given these findings, it is recommended that current IOPTH criteria should continue to be applied to all patients undergoing parathyroidectomy for sporadic primary hyperparathyroidism.
mone immunoassay type used. Second, parathyroid hormone half-life increases with increasing body mass index, particularly in young patients. Third, parathyroid hormone half-life is independent of bisphosphonate use, biochemical disease severity, and, surprisingly, renal function. However, the article also has a flaw. Multiglandular disease that has been missed at exploration typically presents as biochemical persistence or recurrence detected in long-term followup, which is why the time-tested proof that only a single adenoma was present is durable cure. Because some of the studied patients had as little as 6 days of postoperative follow-up, the presented data do not verify the premise that all studied patients indeed had a single adenoma and we therefore cannot assume all to be cured. Taken together, the valuable findings described by Leiker et al will help us to further refine an already highly successful approach. These findings also serve to highlight new challenges in the current management of primary hyperparathyroidism. Over decades, for example, the biochemical, and anatomical, presentation of primary hyperparathyroidism has become more subtle while some patient factors that hinder success, such as obesity, are better recognized. 8, 9 Endocrine surgeons are by definition detail oriented and outcome based and continue to pursue the Holy Grail for our patients, the perfect operative outcomes.
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